Prevalence of anti-drug antibodies against interferon beta has decreased since routine analysis of neutralizing antibodies became clinical practice
- 2 May 2012
- journal article
- research article
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 18 (12) , 1775-1781
Abstract
Neutralizing antibodies (NAbs) against interferon beta (IFNβ) lead to loss of treatment efficacy in multiple sclerosis patients. The seroprevalence of NAbs in multiple sclerosis patients treated with IFNβ during 2003–2004 was 32% in a cross-sectional analysis of routine data. The aim of this study was to investigate whether the seroprevalence of NAbs, the levels of NAb titres and the IFNβ preparations used for treatment of multiple sclerosis patients had changed in 2009–2010. This study included 1296 patients, analysed for NAbs with the myxovirus resistance protein A gene expression assay in 2009–2010. The seroprevalence of NAbs had decreased to 19% in 2009–2010, which is significantly lower compared with the previous study in 2003–2004 (pp<0.0001). NAb seroprevalence has decreased since NAb monitoring became clinical practice in 2003, especially for patients with high NAb titres. This might be due to the stricter monitoring of NAb titres that prompt NAb positive patients to stop treatment, to preferential use of less immunogenic drugs and to alteration of drug formulations.Keywords
This publication has 27 references indexed in Scilit:
- Frequency and Magnitude of Interferon β Neutralizing Antibodies in the Evaluation of Interferon β Immunogenicity in Patients with Multiple SclerosisJournal of Interferon & Cytokine Research, 2011
- Routine interferon-neutralising antibody testing in patients with relapsing-remitting multiple sclerosisJournal of the Royal College of Physicians of Edinburgh, 2010
- Influence of interferon-beta therapy switching on neutralizing antibody titres: results from the Austrian Switch StudyMultiple Sclerosis Journal, 2009
- Absence of MxA induction by interferon β in patients with MS reflects complete loss of bioactivityNeurology, 2009
- Neutralizing antibodies against interferon beta: fluctuation is modest and titre dependentEuropean Journal of Neurology, 2008
- Predictive markers for response to interferon therapy in patients with multiple sclerosisNeurology, 2008
- Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of Interferon-betaMultiple Sclerosis Journal, 2007
- Immunogenicity and tolerability of an investigational formulation of interferon-β1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosisClinical Therapeutics, 2007
- Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicityMultiple Sclerosis Journal, 2007
- A multicenter, open-label, phase II study of the immunogenicity and safety of a new prefilled syringe (liquid) formulation of avonex in patients with multiple sclerosisClinical Therapeutics, 2004